CSL's Se­qirus, spurred on by Covid-19 mR­NA vac­cines, props up new unit for 'self-am­pli­fy­ing' shot tech

The Covid-19 pan­dem­ic has of­fered proof of con­cept for the promise of mR­NA vac­cines, and now CSL Behring’s Se­qirus unit wants to take the next step with tech­nol­o­gy it thinks will dri­ve the field even fur­ther in­to the fu­ture.

Se­qirus will carve out a new busi­ness unit built around its self-am­pli­fy­ing mR­NA vac­cine work against in­fluen­za, the com­pa­ny said Thurs­day, be­com­ing the lat­est ma­jor play­er to dive head­first in­to the field af­ter the suc­cess of the Covid-19 jabs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER